Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model

@article{Kolik2019ComparativeAO,
  title={Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model},
  author={L. Kolik and M. Konstantinopolsky},
  journal={Bulletin of Experimental Biology and Medicine},
  year={2019},
  volume={166},
  pages={739-743}
}
Activities of noncompetitive NMDA receptor antagonists (aminoadamantane derivatives) were assessed in random-bred rats with modeled morphine withdrawal syndrome. A single intraperitoneal injection of hemantane (10 or 20 mg/kg) significantly and dose-dependently moderated some behavioral symptoms (teeth-chattering, ptosis, and vocalization) and reduced total score of morphine withdrawal syndrome. In morphine-abstinent rats, hemantane partially prevented the decrease in the thresholds of tactile… Expand

References

SHOWING 1-10 OF 18 REFERENCES
The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans
[Afobazole decreases severity of morphine withdrawal syndrome: experimental evidence].
Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome.
Further evidence for a role of NMDA receptors in the locus coeruleus in the expression of withdrawal syndrome from opioids
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Amantadine as Augmentation in Managing Opioid Withdrawal with Clonidine: a randomized controlled trial
...
1
2
...